探索XDH基因变异与痛风中血清尿酸酸和桑丁脱酶水平之间的关系
Juan Alan Román-Olmos1, Yessica Zamudio-Cuevas2, Karina Martínez-Flores2
1División de Reumatología, Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico.
Clinical rheumatology
|February 23, 2026
概括
XDH rs17323225 TT基因型与墨西哥人的痛风风险增加和更高的尿酸盐水平有关. 这一发现可能有助于识别容易患上痛风的个人,以便进行个性化治疗.
科学领域:
- 遗传学 是一个遗传学.
- 生物化学 生化学
- 类风湿病学 类风湿病学
背景情况:
- 痛风是一种痛苦的炎症性关节炎,由血清尿酸水平升高引起.
- 丁脱酶 (XDH) 酶活性对于尿酸盐生物合成至关重要.
- XDH基因的遗传变异会影响酶功能和尿酸的产生.
研究的目的:
- 研究两个XDH基因单核酸变体 (SNVs) 与墨西哥人口中痛风易感性之间的关联.
- 探索这些SNV与血清尿酸盐和XDH水平的相关性.
主要方法:
- 在41名痛风患者和40名对照中使用实时PCR对XDHSNVs (rs17323225和rs17011368) 的基因定型.
- 通过色度测定和ELISA分别测量血清尿酸盐和XDH水平.
- 对基因型分布的分析和用于关联估计的后勤回归.
主要成果:
- 与对照组相比,痛风患者的血清尿酸和XDH水平显著更高.
- XDH rs17323225变体的TT基因型与痛风风险增加有关 (OR=3.69,p=0.04).
- 具有rs17323225 TT基因型的个体表现出更高的酸盐和XDH水平.
结论:
- XDH rs17323225变异可能成为墨西哥人口中痛风的遗传风险因素.
- XDH的遗传变异性有助于尿酸代谢失调.
- XDH基因定型可以帮助识别患上痛风的基因风险较高的个体,促进个性化预防和治疗策略.
![Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F61682.jpg&w=3840&q=50)
相关概念视频
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
26
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
26
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
20
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
20
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
30
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
30
01:16Drug toxicity: Idiosyncratic Reactions
50
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
50
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
27
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
27
01:11Genome-wide Association Studies-GWAS
15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.9K